Thermo Fisher Scientific Inc. has completed its acquisition of Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company.
 
Mesa Biotech has developed the Accula System, a point-of-care PCR-based testing platform for infectious disease diagnosis. The platform enables rapid, highly accurate testing at physician offices, pharmacies and other settings, providing results in 30 minutes. Beyond COVID-19 testing, Mesa Biotech’s existing platform includes tests for flu, respiratory syncytial virus (RSV), and Strep A.

Mesa Biotech will become part of the Life Sciences Solution Segment and is expected to add revenue of approximately $200 million in 2021.
 
“Mesa Biotech is an important part of our strategy to expand the benefits of molecular diagnostics at the point of care, starting with COVID-19 testing,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. “By combining Thermo Fisher’s operational excellence, access to raw materials and existing distribution and sales channels with Mesa’s innovative platform, we can rapidly scale manufacturing volume, drive cost efficiencies and bring much-needed diagnostics to market faster and at greater scale.”